TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Rachel A Freedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.